Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca's heart drug Brilinta fails in trial

Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
AstraZeneca's heart drug Brilinta fails in trial
Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, but not enough to hit targets

AstraZeneca PLC (LON:AZN) said stroke treatment Brilinta was not as effective as expected in trials, hitting hopes that it would be a flagship new drug.

AstraZeneca said a study of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA), had shown the drug had not met its primary efficacy endpoint of preventing repeat attacks within 90 days.

Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, heart attack or died than those on aspirin, but the difference was not statistically significant.

AstraZeneca's executive vice-president of global medicine development and chief medical officer, Sean Bohen, said: "We will present the full analysis of the trial results, including  subgroups, at a forthcoming stroke congress and will engage with regulatory agencies on the interpretation of the data."

The so-called Socrates trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients over 40 years-old with an acute ischaemic stroke.

Shares in AstraZeneca fell 3.5p to 3911.5p.

 

 

 

 

 

 

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use